Trial of three drugs plus temodar
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Combination of Repurposed Drugs plus Temodar |
| FDA Approval | Varies (individual drugs have separate FDA approvals for other conditions) |
| Used for | Investigational use in glioblastoma |
| Clinical Trial Phase | Phase 1 and Phase 2 trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Varies based on the combination; potential for increased chemotherapy toxicity |
| OS without | Standard treatment: median survival of 16.1 months |
| OS with | Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid |
| PFS without | Not specified |
| PFS with | Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 4 |
| Toxicity Explanation | The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed. |
Notes: Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.
From Ben Williams Book: Not specified
Loading comments...
